Advanced
Soft Ionization of Metallo-Mefenamic Using Electrospray Ionization Mass Spectrometry
Soft Ionization of Metallo-Mefenamic Using Electrospray Ionization Mass Spectrometry
Mass Spectrometry Letters. 2015. Jun, 6(2): 43-47
Copyright © 2015, Korean Society Mass Spectrometry
All MS Letters content is Open Access, meaning it is accessible online to everyone, without fee and authors’ permission. All MS Letters content is published and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/). Under this license, authors reserve the copyright for their content; however, they permit anyone to unrestrictedly use, distribute, and reproduce the content in any medium as far as the original authors and source are cited. For any reuse, redistribution, or reproduction of a work, users must clarify the license terms under which the work was produced.
  • Received : March 15, 2015
  • Accepted : May 26, 2015
  • Published : June 30, 2015
Download
PDF
e-PUB
PubReader
PPT
Export by style
Share
Article
Author
Metrics
Cited by
TagCloud
About the Authors
Hani Nasser Abdelhamid
Department of Chemistry, Assuit University, Assuit, 71515, Egypt
Hui-Fen Wu
School of Pharmacy, College of Pharmacy, Kaohsiung Medical University, Kaohsiung, 800, Taiwan
hwu@faculty.nsysu.edu.tw

Abstract
Detection of mefenamic acid (M, non-steroidal anti-inflammatory drug, NSAIDs) and its metallodrug was investigated using electrospray ionization mass spectrometry (ESI-MS) and fluorescence spectroscopy. ESI-MS data (500 µL, 1×10-3 M) revealed high detection sensitivity for the drug and metallodrug. ESI-MS spectra revealed peaks at 242, 580, and 777 Da corresponding to [M+H]+, [63Cu(M-H)2(H2O)2+H]+, and [56Fe(M-H)3+H]+, respectively. The metal:mefenamic ratios of ESIMS spectra are in complete agreement with the fluorescence spectroscopy results (1:2 for Cu(II) and 1:3 for Fe(III)). ESI is a soft ionization technique that can be used on labile metallo-mefenamic acids and is promising for the detection of these species in environmental samples and biological fluids.
Keywords
Introduction
Interactions of metals and biomolecules such as proteins, drugs, cells and others are very important for separation, as biological agents, etc. 1 - 7 Probing metallodrugs (interactions between metals and drugs) is critical to address biological concerns due to the toxicity of the new species. 8 Among the different techniques available, electrospray ionization mass spectrometry (ESI-MS) is a soft ionization technique that can be used to study metallodrugs and their interactions with biomolecules. 9 - 13 ESI-MS requires a small volume of the analyte, low concentration, and is tolerated by contaminants such as buffers and salts. 14 - 16 Furthermore, it is often used for protic and aprotic solvents. 17 The application of ESI-MS for the analysis of transition metal complexes was reviewed in Ref.. 18 ESI-MS can also be used for metallodrug-protein interactions 19 and for labile drugs. 20 ESI-MS has been employed to determine the binding or dissociation constants of zinc finger peptides (ZFPs), 21 to characterize a Ru(III) anticancer drug, 22 for Protein metalation processes, 23 and also to characterize antiproliferative activity 24 and cytotoxic metallodrugs. 25 A review of the applications of hyphenated techniques for metal-based pharmaceuticals has been published.
Mefenamic acid (MFA) is a non-steroidal antiinflammatory drug (NSAID) used to treat pain, including menstrual pain. It was marketed as Ponstel and Postan in the USA and UK, respectively. Kidney and liver deficiencies may cause accumulation of the drug and its metabolites in the excretory system. It is also important to note that overdoses of MFA produce metabolite accumulation that causes acute hepatic necrosis, inducing morbidity and mortality in humans. Therefore, detection of this drug is valuable due to environmental, medical and forensic science concerns. Thus, detection of the drug has been investigated using various techniques, such as high-performance liquid chromatography (HPLC), gas chromatography-mass spectrometry (GC–MS), spectroph-otometric methods, and capillary electrochromatography. 27 - 36 A new analytical technique is required with a better limit of detection (LOD), good performance and high speed.
The detection of mefenamic acid and its metallodrugs using electrospray ionization as a simple and effective analytical tool is described for the first time in this report. The coordination chemistry for mefenamic acid with the transition metals “Cu(II) and Fe(III)” is also reported. The metallodrugs were confirmed using fluorescence spectroscopy. The molar ratios determined using electrospray ionization mass spectrometry (ESI-MS) and fluorescence spectroscopy are in good agreement.
Experimental
Chemicals. CuSO 4 .5H 2 O and ponstel drug (used as pure Mefenamic acid without any additives) were purchased from Sigma Company (China). FeCl 3 .6H 2 O was purchased from Riedel-de Haën (Seelze, Germany). Methanol (HPLC grade) was purchased from Merck (USA). All the chemicals were used directly without further purification. De-ionized water (18 M purified Millipore water, USA) was used to prepare all of the solutions.
ESI(+)-MS measurements were performed using Finnigan MAT ion trap mass spectrometer (Finnigan LCQAdvantages, San Jose, CA, USA). A microsyringe pump (Harvard Apparatus, Edenbridge, Great Britain) was used to inject the sample solution. All mass spectra were obtained in positive ion mode. The ion trap analyzer was operated at a pressure of ~1.5×10 -5 Torr, and capillary temperature was 200℃. ESI spray needle voltage was fixed at 4.50 kV. A tube lens offset voltage of 80.0 kV and capillary voltage of 9.59 kV were used to obtain ESI-MS spectra. Sheath gas flow rate (arb.) during the experiments was 18.90. Each mass spectrum was the average of 3 individual scans. All mass spectra were recorded on freshly prepared solutions in the mass range of 0-1000 Da.
The fluorescence spectra were obtained from a fluorescence spectrophotometer (F-2700 Hitachi Co., Japan) equipped with a xenon arc lamp (150 W). The scan speed was set to 120 nm min-1 and 5 nm spectral slit widths were used for excitation and emission in 5 nm step sizes. Emission spectra were recorded using 360 nm excitation. All spectra were visualized using Origin V6.0.
The molar ratio method was applied to determine the stoichiometry of the complex in solution using fluorescence spectroscopy. A stock solution of the drug (1.0×10 -3 M) was prepared in 50% (v/v) methanol. Metal solutions of Cu(II) and Fe(III) (1.0×10 -3 M) were prepared in deionized water. The metal concentrations were kept constant while different molar ratios of the drug (1:0.5, 1:1,1:1.5,1:4) were added to the metal solution at pH 7.4 (phosphate buffer solution, PBS) and incubated 10 min before measurements. Fluorescence spectroscopy was measured at λ ex = 360 nm.
ESI-MS measurements. Mefenamic acid (1.0×10 -3 M) was mixed with the appropriate molar ratio of metal solutions (1.0×10 -3 M) with 1.0 mL of ammonium acetate buffer solution (pH = 7.4). The stock solution was incubated for 10 min before mass analysis. All spectra were collected at least three times to confirm repeatability.
Results and Discussion
A few analytical tools have been proven to be capable of drug and metallodrug detections. Among these techniques, electrospray ionization mass spectrometry (ESI-MS) is simple, sensitive and can be employed for qualitative and quantitative analysis. The main reason is that the bonds between anticancer metallodrugs and model proteins are labile and easy to destroy. Therefore, ESI-MS can be used for the molecular characterization of these adducts, as described by Messori and co-workers. 37 Mefenamic acid (M) has a nominal mass of 241.2Da. The ESI(+)-MS spectrum ( Figure 1 ) peaks at m/z 242.1 correspond to the protonated drug i.e [M+H] + . The inset in Figure 1 represents the peak assignments of the drug related ions. ESI-MS ( Figure 1 ) showed a dehydration peak for the drug at m/z 224.9, corresponding to [M-H 2 O+H] + . The peak at m/z 483.0 corresponds to the drug dimer, i.e [2M+H] + . ESI-MS did not affect the non-covalent bond in the dimer peak ( m/z 465, [2M-H 2 O+H] + ). Detection of the dimer species indicates that ESI-MS is a soft ionization technique for non-covalent interactions. The peak assignments and limit of detection are listed in Table 1 . The data reveals that ESI-MS is highly sensitive over other techniques as shown in Table 2 . The data also shows that mefenamic acid can be detected using fluorescence and mass spectrometry. It is well known that the latter has higher sensitivity compared to other methods.
PPT Slide
Lager Image
ESI-MS spectrum for mefenamic acid.
ESI-MS assignments and LOD for mefenamic acid and their metallodrug
PPT Slide
Lager Image
ESI-MS assignments and LOD for mefenamic acid and their metallodrug
Comparison of the present method with other methods for extraction and determination of mefenamic acid
PPT Slide
Lager Image
Note: SBSE-HPLC-DAD, stir bar sorptive extraction- high performance liquid chromatography –diode array detection; HFLPME-HPLC , Hollow fiber-based liquid phase microextraction-high performance liquid chromatography; microwave assisted extraction-solid phase extraction-gas chromatographytandem mass spectrometry
Mefenamic acid is an N-anthranilic acid derivative with carboxylic and amine groups as the main function groups. Fluorescence emission of Cu(II)-mefenamic acid ( Figure 2 A) and Fe(III)-mefenamic acid ( Figure 2 B) can be used to probe the metallodrug formation in the liquid phase. Fluorescence spectra ( Figure 2 (A-B)) of mefenamic acid display emission were obtained at 475 nm. The emission was shifted to a lower wavelength upon complexation with metals such as Cu(II) ( Figure 2 A) and Fe(III) ( Figure 2 B). The molar ratio of the metal complexes in the metallodrug was determined independently using fluorescence emission as in Figure 2 (A-B). The molar ratio using fluorescence emission showed that the ratios were 1:2 and 1:3 for Cu(II) and Fe(III) complexes, respectively ( Figure 2 C). Mefenamic acid has been reported to react with different metals at ambient temperature, physiological pH (i.e 7.4) and contact time of 10 min 38. The ESI(+)-MS spectrum of Cu(II)-mefenamic acid ( Figure 3 ) shows a low resolution, which may be due to the instability of the complex, or its low volatility. The peak assignments are inserted in Figure 3 and listed in Table 1 . The spectrum ( Figure 3 ) shows peaks at 580, 543, and 310 Da corresponding to [ 63 Cu(M-H) 2 (H 2 O) 2 +H] + , [ 63 Cu(MH) 2 +H] + and [ 63 CuC 14 H 14 O 4 +H] + , respectively. In contrast with the Cu(II)-mefenamic acid complex, the ESI-MS ( Figure 4 ) for the Fe(III)-mefenamic acid complex showed better resolution. The spectrum contained a peak at m/z 777.0 Da that was assigned to [ 56 Fe(M-H) 3 +H] + . This peak agreed with the molar ratio data in Figure 2 C i.e 1:3. Peak assignments and LOD are listed in Table 1 .
PPT Slide
Lager Image
Fluorescence emission of mefenamic acid and their metal complexes, (A) Cu (II) (B) Fe(III) and (C) molar ratio analysis.
PPT Slide
Lager Image
ESI-MS spectrum for Cu(II)-mefenamic acid.
PPT Slide
Lager Image
ESI-MS for Fe(III)-mefenamic acid complex.
ESI-MS, a soft ionization method, generates multiplycharged species of the target analyte, hence, it is very useful for studying metallodrug-protein interactions. It is also extremely effective for investigating interactions between selected metallodrugs and one or a few isolated proteins in the sample. As shown in Table 2 , ESI-MS is simple, sensitive and effective for mefenamic acid. 39 - 45
It is important to stress that most technique is not recommended for the detection of metallodrug species. This is due to the high sensitivity of the non-covalent bonds, which are very labile and can be destroyed. Thus, ESI-MS was used only for complexes involving metallodrugs. 18 The data revealed that ESI-MS is apparently a simpler, more sensitive and soft ionization approach for metallo-mefenamic detection.
Conclusion
ESI-MS has been introduced as a new analytical tool to characterize a non-steroidal anti-inflammatory drug (mefenamic acid) and its metallodrugs. ESI-MS is simple, sensitive and efficient for metallodrug analysis. The technique also provides high resolution, high throughput, low sample load and soft ionization for metallodrug detection. The ESI-MS data was validated by fluorescence spectroscopy.
Acknowledgements
The authors are grateful to the Ministry of Science and Technology of Taiwan for the financial support.
References
Wu H. F. , Gopal J. , Abdelhamid H. N. , Hasan N. 2012 Proteomics 12 2949 -    DOI : 10.1002/pmic.201200295
Abdelhamid H. N. , Wu H. F. 2013 J. Mater. Chem. B 1 3950 -    DOI : 10.1039/c3tb20413h
Abdelhamid H. N. , Wu H. F. 2013 J. Mater. Chem. B 1 6094 -    DOI : 10.1039/c3tb21020k
Abdelhamid H. N. , Master's thesis 2013 Applications of nanomaterials and organic semiconductors for bacteria & biomolecules analysis/biosensing using laser analytical spectroscopy National Sun-Yat Sen university Master's thesis
Abdelhamid H. N. , Wu H. F. 2014 J. Am. Soc. Mass Spectrom. 25 861 -    DOI : 10.1007/s13361-014-0825-z
Abdelhamid H. N. , Wu H. F. 2014 RSC. Advances 4 53768 -    DOI : 10.1039/C4RA07638A
Gopal J. , Abdelhamid H. N , Hua P. Y. , Wu H. F. 2013 J. Mater. Chem. B 1 2463 -    DOI : 10.1039/c3tb20079e
Krauss I.R. , Messori L. , Cinellu M.A. , Marasco D. , Sirignano R. , Merlino A. 2014 Dalton Trans. 43 17483 - 17488    DOI : 10.1039/C4DT02332C
Timerbaev A. R. , Pawlak K. , Gabbiani G. , Messori L. 2011 Trends. Anal. Chem. 7 1120 -    DOI : 10.1016/j.trac.2011.03.007
Abdelhamid H. N. , Wu H .F. 2012 Anal. Chim. Acta. 751 94 -    DOI : 10.1016/j.aca.2012.09.012
Sekar R. , Kailasa S. , Abdelhamid H. N. , Chen Y. C. , Wu H. F. 2013 Inter. J. Mass Spectrom. 338 23 -    DOI : 10.1016/j.ijms.2012.12.001
Petkovic M. , Kamceva T. 2011 Metallomics 3 550 -    DOI : 10.1039/c0mt00096e
Claereboudt J. , de Spiegeleer M. , de Bruijn B. E. , Gijbels R. , Claeys M. 1989 J. Pharm. Biomed. Anal. 7 1599 -    DOI : 10.1016/0731-7085(89)80171-2
Melanie D. , Eelman Johanna M. , Blacquiere B. , Moriarty M. M. , Fogg E. 2008 Angew. Chem. Int. Ed. 47 303 -    DOI : 10.1002/anie.200704489
Ross A. , Ikonomou M. , Thompson J. , Orians K. 1998 Anal. Chem. 70 2225 -    DOI : 10.1021/ac9711908
Matsumoto A. , Fukumoto T. , Adachi H. , Watarai H. 1998 Anal. Chim. Acta 390 193 -    DOI : 10.1016/S0003-2670(99)00222-6
Walton W. L. , Joshi U. , Dzyuba S. V. , Youngblood W. J. , Verbeck G. F. 2013 Rapid Commun. Mass Spectrom. 27 1954 -    DOI : 10.1002/rcm.6653
Poon G. K. , Bisset G. G. , Prakash M. 1993 J. Am. Soc. Mass Spectrom. 4 588 -    DOI : 10.1016/1044-0305(93)85020-X
Messori L. , Marzo T. , Sanches R. N. F. , Rehman H. , De Oliveira Silva D. 2014 A. MerlinoAngewandte Chemie - International Edition 53 6172 -    DOI : 10.1002/anie.201403337
Khan N. , Abdelhamid H. N. , Yan J. Y. , Chung F. T. , Wu H. F. 2015 Anal. Chem. Research 3 89 -    DOI : 10.1016/j.ancr.2015.01.001
Lee C. S. , Park S. J. , Lee J. Y. , Park S. , Jo K. , Oh H. B. 2015 Mass Spectrom. Lett. 6 7 -    DOI : 10.5478/MSL.2015.6.1.7
Jarosz M. , Matczuk M. , Pawlak K. , Timerbaev A. R. 2015 Analytica Chimica Acta 851 72 -    DOI : 10.1016/j.aca.2014.08.031
Gabbiani C. , Michelucci E. , Messori L. , Massai L. , Maiore L. , Scaletti F. , Agostina Cinellu M. 2012 J. Biol. Inorg. Chem. 17 1293 -    DOI : 10.1007/s00775-012-0952-6
Porchia M. , Dolmella A. , Gandin V. , Marzano C. , Pellei M. , Peruzzo V. , Refosco F. , Santini C. , Tisato F. 2013 European Journal of Medicinal Chemistry 59 218 -    DOI : 10.1016/j.ejmech.2012.11.022
Marzo T. , Savic A. , Massai L. , Michelucci E. , Sabo T. J. , Grguric-Sipka S. , Messori L. 2015 Biometals 28 425 -    DOI : 10.1007/s10534-015-9839-7
Meermann B. , Sperling M. 2012 Anal. Bioanal. Chem. 403 1501 -    DOI : 10.1007/s00216-012-5915-9
Niopas I. , Mamzoridi K. 1994 J. Chromatogr. B 656 447 -    DOI : 10.1016/0378-4347(94)00116-2
Kole P. L. , Millership J. , McElnay J. C. 2011 Talanta 85 1948 -    DOI : 10.1016/j.talanta.2011.07.016
Çakirer O. , Kiliç E. , Atakol O. , Kenar A. 1999 J. Pharm. Biomed. Anal. 20 19 -    DOI : 10.1016/S0731-7085(98)00044-2
Araujo L. , Wild J. , Villa N. , Camargo N. , Cubillan D. , Prieto A. 2008 Talanta 75 111 -    DOI : 10.1016/j.talanta.2007.10.035
Espinosa Mansilla A. , Munoz de la Pena A. , D. Gonzalez Gomez D. 2005 Anal. Biochem. 347 275 -    DOI : 10.1016/j.ab.2005.09.032
Macia A. , Borrull F. , Calull M. , Aguilar C. 2006 J. Chromatogr. A 1117 234 -    DOI : 10.1016/j.chroma.2006.03.076
Dinç E. , Yücesoy C. , Onur F. 2002 J. Pharm. Biomed. Anal 28 1091 -    DOI : 10.1016/S0731-7085(02)00031-6
Williams R. E. , Cottrell L. , Jacobsen M. , Bandara L.R. , Kelly M. D. , Kennedy S. , Lock E. A. 2003 Biomarkers 8 472 -    DOI : 10.1080/13547500310001647030
Jawla S. , Jain S. 2010 Int. J. Pharm. Sci. Drug Res. 2 45 -
Santini A. , Pezza H. , Pezza S. 2007 Actuators B. Chem. 128 117 -    DOI : 10.1016/j.snb.2007.05.039
Casini A. , Guerri C. , Gabbiani L. , Messori J. 2008 J. Inorg. Biochem. 102 995 -    DOI : 10.1016/j.jinorgbio.2007.12.022
Edriss M. , Razzahi N. , Madjidi B. 2008 Turk. J. Chem. 32 505 -
Messori L. , Merlino A. 2014 Inorg. Chem. 53 3929 -    DOI : 10.1021/ic500360f
Silva A. R. M. , Portugal F. C. M. , Nogueira J. M. F. 2008 J. Chromatogr. A 1209 10 -    DOI : 10.1016/j.chroma.2008.08.103
Ramos Payan M. , Bello Lopez M. A. , FernandezTorres R. , Perez Bernal J. L. , Callejon Mochon M. 2009 Anal. Chim. Acta 653 184 -    DOI : 10.1016/j.aca.2009.09.018
Madrakian T. , Afkhami A. , Mohammadnejad M. 2009 Anal. Chim. Acta 645 25 -    DOI : 10.1016/j.aca.2009.05.002
Azzouz A. , Ballesteros E. 2012 Sci. Total Environ. 419 208 -    DOI : 10.1016/j.scitotenv.2011.12.058
Rezaei F. , Yamini Y. , Moradi M. , Ebrahimpour B. 2013 Talanta 105 173 -    DOI : 10.1016/j.talanta.2012.11.035
Keith-Roach M. 2010 J. Anal. Chim. Acta 678 140 -    DOI : 10.1016/j.aca.2010.08.023